ArticleBlood cancer discovery2021
Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Open access · bronzeAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Selective and Potent First-in-Class CRBN-Dependent Molecular Glue Degraders of WW Domain-Binding Protein 4.Angewandte Chemie (International ed. in English) · 2026Article
- Cancer-associated fusion transcripts: mechanisms, functional roles, and clinical implications.Clinical and experimental medicine · 2026Review
- Article
- Molecular glue degraders: Rational design, specificity engineering, and advanced delivery.Acta pharmaceutica Sinica. B · 2026Review
- Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer.Oncology research · 2026Review
- Neural crest induction requires SALL4-mediated BAF recruitment to lineage specific enhancers.Development (Cambridge, England) · 2025Article
- Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.Molecular cell · 2025Article
- Unveiling the hidden interactome of CRBN molecular glues.Nature communications · 2025Article
- Targeting theBiomedicines · 2025Article
- Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy.Nature communications · 2025Article
- Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation.Journal of hematology & oncology · 2024Article
- Molecular glue degrader for tumor treatment.Frontiers in oncology · 2024Review
- Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.Nature communications · 2023Article
- Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.Acta pharmacologica Sinica · 2023Article
- Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents.RSC advances · 2022Article
- CRL4Cancers · 2022Review
- Review
- Linear and Circular Long Non-Coding RNAs in Acute Lymphoblastic Leukemia: From Pathogenesis to Classification and Treatment.International journal of molecular sciences · 2022Review
- Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.Journal of personalized medicine · 2021Review
- Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins.Blood cancer discovery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 5 countries.
Aline RennevilleBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-0805-9640
Jessica A GasserBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Daniel E GrinshpunBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Pierre M Jean BeltranBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Namrata D UdeshiBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Mary E MatyskielaCelgene/Bristol-Myers Squibb Corporation, San Diego, California.
Thomas ClaytonCelgene/Bristol-Myers Squibb Corporation, San Diego, California.ORCID 0000-0001-5930-3450
Marie McConkeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kaushik ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alexander TepperBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Andrew A GuirguisBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-3134-0596
Rob S SellarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sophie CotteretDépartement de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif, France.
Christophe MarzacDépartement de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif, France.
Véronique SaadaDépartement de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif, France.
Stéphane De BottonDépartement d'Hématologie, Gustave Roussy Cancer Campus, Villejuif, France.
Jean-Jacques KiladjianUniversité de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques CIC 1427, INSERM, Paris, France.
Jean-Michel CayuelaHematology Laboratory and EA3518, University Hospital Saint-Louis, Université de Paris, Paris, France.
Mark RolfeCelgene/Bristol-Myers Squibb Corporation, San Diego, California.
Philip P ChamberlainCelgene/Bristol-Myers Squibb Corporation, San Diego, California.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-7203-4299
Benjamin L EbertBroad Institute of MIT and Harvard, Cambridge, Massachusetts. Benjamin_Ebert@dfci.harvard.edu.
Broad Institute · USBristol-Myers Squibb (Switzerland) · CHInstitut Gustave Roussy · FRDana-Farber Cancer Institute · USInserm · FRSaint Louis University Hospital · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6MTyrosine Kinases, Serine-Threonine Kinases,&Phosophatases in PathogenesisP01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERRY, DONALD A · 2005 to 2009
$9.7MMICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4MThe role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9MNCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108631NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA253125NCI NIH HHS U01 CA214125NCI NIH HHS U24 CA210986NHLBI NIH HHS R01 HL082945
Abstract
Thalidomide analogs exert their therapeutic effects by binding to the CRL4
Indexed as
Hematologic NeoplasmsThalidomideDNA-Binding ProteinsHumansLenalidomideOncogene ProteinsTranscription FactorsDNA-Binding ProteinsLenalidomideOncogene ProteinsThalidomideTranscription FactorsZMYM2 protein, humanfusion oncoproteinshematologic malignanciesthalidomide analogsubiquitinationzinc finger protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.